How cell cycle proteins affect heart sensitivity to cancer treatment
Cell cycle proteins as key regulators of cardiac chemosensitivity
This study is looking at how certain proteins in our cells affect the heart's reaction to a common cancer treatment called doxorubicin, with the goal of finding ways to protect the heart from damage during chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington State University NIH-funded |
| Lab location | 1 site (Pullman, United States) |
| Project ID | NIH-10767884 on NIH RePORTER |
What this research studies
This research investigates the impact of cell cycle proteins on the heart's response to anthracycline-based chemotherapy, particularly focusing on doxorubicin. It aims to understand how these proteins regulate cardiomyocyte apoptosis, which is a significant factor in the cardiotoxic effects of cancer treatment. By exploring the mechanisms behind this process, the research seeks to identify potential strategies for protecting the heart during chemotherapy. Patients may benefit from insights that could lead to improved treatment protocols that minimize heart damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult cancer patients who are receiving anthracycline-based chemotherapy and are at risk of heart-related side effects.
Not a fit: Patients who are not undergoing anthracycline-based chemotherapy or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer chemotherapy options for cancer patients, reducing the risk of heart damage.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of cardiotoxicity related to chemotherapy, indicating that this approach has potential for success.
Where this research is happening
Pullman, United States
- Washington State University — Pullman, United States (Active)
Researchers
- Principal investigator: Cheng, Zhaokang — Washington State University
- Study coordinator: Cheng, Zhaokang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.